Neuroscience Letters 591 (2015) Christian Moritz, Francesco Berardi, Carmen Abate and Francesca Peri View Paper Post navigationPreviousPrevious post:Anavex to Present at Sigma-1 Receptors SymposiumNextNext post:Anavex Appoints Epilepsy and Clinical Trial Methodology Expert to Scientific Advisory BoardRelated PostsAnavex Life Sciences Presents New Three-Year, Longitudinal Clinical Efficacy Data for ANAVEX®2-73 in Alzheimer’s Disease at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD) MeetingOctober 26, 2018Anavex Life Sciences to Present at the 2018 Cantor Fitzgerald Global Healthcare ConferenceSeptember 26, 2018First Patient Enrolled in Anavex Life Sciences Phase 2b/3 Clinical Trial of ANAVEX®2-73 for the Treatment of Early Alzheimer’s DiseaseAugust 28, 2018Anavex Life Sciences Presents New Data Identifying Treatment Response Biomarkers in Alzheimer’s Disease Patients Treated with Investigational ANAVEX®2-73 at 2018 Alzheimer’s Association International Conference (AAIC)July 25, 2018
Anavex Life Sciences Presents New Three-Year, Longitudinal Clinical Efficacy Data for ANAVEX®2-73 in Alzheimer’s Disease at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD) MeetingOctober 26, 2018
Anavex Life Sciences to Present at the 2018 Cantor Fitzgerald Global Healthcare ConferenceSeptember 26, 2018
First Patient Enrolled in Anavex Life Sciences Phase 2b/3 Clinical Trial of ANAVEX®2-73 for the Treatment of Early Alzheimer’s DiseaseAugust 28, 2018
Anavex Life Sciences Presents New Data Identifying Treatment Response Biomarkers in Alzheimer’s Disease Patients Treated with Investigational ANAVEX®2-73 at 2018 Alzheimer’s Association International Conference (AAIC)July 25, 2018
